VigiAMS
v2.0 — ICMR AMSP aligned

Antimicrobial Stewardship,
Simplified for Indian Hospitals.

ICMR-aligned AMSP software covering every pillar — antibiogram, DDD/DOT usage tracking, restricted-drug approvals, prophylaxis audits, HAI surveillance, and outbreak alerts. On web and Android.

Built on ICMR AMSP guidelines CLSI M39 & M100 compliant WHO AWaRe categorization
app.vigiams.in / dashboard
LIVE
MDRO Rate
14.2%
↓ 0.8 vs Q1
Pending Approvals
7
3 over 48h
DDD / 1000 PD
642
+12 MoM
WHO AWaRe — consumption Target: Access ≥ 60%
Access 61.4 Watch 30.2 Reserve 8.4
Facility Antibiogram · CLSI M39 Q2 2026 · n=274
CLABSI
1.8 /1k device-days
CAUTI
2.1 /1k device-days
VAP
4.7 /1k device-days
The problem

Antimicrobial resistance is India's silent crisis. Most hospitals still track stewardship in spreadsheets, miss outbreak signals, and can't generate a CLSI-compliant antibiogram on demand. VigiAMS fixes that.

Modules

Eight pillars. One platform.

Every ICMR AMSP requirement, available out of the box — and integrated end-to-end.

Platforms

Built for the committee. Built for the bedside.

Web Dashboard

For the AMS Committee.

Full management console — bulk culture imports, antibiogram editor, restricted-drug list governance, audit reports, and one-click ICMR/NABH exports.

  • Bulk import from CSV / Excel / HL7
  • Antibiogram builder with MDRO flags
  • Committee approvals + audit trail
  • Exportable NABH-ready reports
Committee · Q2 2026
Approvals queue
7
Antibiogram
Q2 ✓
DUE audits — last 30 days
Android App

For the ward clinician.

Approvals, audits and dashboards in your pocket. Submit a restricted-drug request from rounds; receive committee feedback within minutes.

  • One-tap approval requests with culture context
  • Push alerts: outbreak, 48h follow-up, decisions
  • Bedside DUE audit forms
  • Biometric login, offline-friendly
09:425G ▰▰▰
Today
Approvals
Pending12m ago
Meropenem 1g q8h
Bed 14 · ICU-2 · Dr. Shah
Review1h ago
Colistin 9MU/day
Bed 03 · ICU-1 · Dr. Rao
Approved3h ago
Vancomycin 1g q12h
Bed 22 · MW · Dr. Iyer
Outbreak2h ago
CRE cluster · ICU-2
3 isolates in 5 days
ApprovalsAuditsDashboardMore
Compliance & Standards

Every metric maps to a published standard.

ICMR AMSP
All 8 pillars
CLSI M39
Antibiogram
CLSI M100
Susceptibility
WHO AWaRe
Access · Watch · Reserve
NABH
Aligned
ABDM
Ready
How it works

From culture log to ICMR report — in four steps.

  1. 01

    Connect your data

    Connect your LIS or upload culture data via CSV, Excel or HL7.

  2. 02

    Auto-generate

    Facility antibiogram + AWaRe metrics computed against the standard.

  3. 03

    Workflows go live

    Approvals, audits, surveillance and outbreak alerts switch on.

  4. 04

    Export reports

    ICMR / NABH-ready reports exported in one click.

Why VigiAMS

Engineered for Indian tertiary care.

Built for India.

ICMR-aligned out of the box. AWaRe-mapped Indian formulary. Supports tertiary-care nuances and multi-facility chains.

Every pillar, one platform.

Replaces 4–5 spreadsheets and standalone tools. One source of truth across microbiology, pharmacy and committee.

Clinician-friendly mobile.

Approvals and audits don't need a desktop. Submit, review and act from the ward in seconds.

Security & deployment

Data sovereign. Audit-ready.

Azure Central India (Pune)
Patient data stays in India.
Encrypted at rest + in transit
TLS everywhere; AES-256 at rest.
Role-based access
Validated at every endpoint.
Complete audit logs
Every read & write recorded.
On-prem option for tertiary chains
Air-gapped deployment available for hospital groups with strict data-residency policies.
Pricing & demo

See VigiAMS running on your hospital's data — in 30 minutes.

No credit card. A clinical lead walks you through your antibiogram, AWaRe split and approvals queue using a sample of your own data.

RN SP VK

Trusted by AMS committees in tertiary-care hospitals across India.

Request a Demo

We'll respond within one business day.

By requesting a demo you agree to our Privacy Policy. We comply with India's DPDP Act 2023.

FAQ

Common questions.